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RISPERIDONE-INDUCED OCULOGYRIC 
CRISIS 
Sir, 
Risperidone in low doses (< 6 mg) is 
reported to be relatively free from extrapyramidal 
side effects including dystonia, akathisia, drug-
induced parkinsonism and tardive dyskinesia 
(Thomas and Lewis, 1998). A double blind study, 
which included 388 schizophrenic patients drawn 
from 20 sites in the United States, reported that 
the incidence of extrapyramidal symptoms in 
patients receiving 6 mg of risperidone was no 
higher than that in patients receiving placebo 
(Marder and Meibach.1994) To our knowledge, 
few cases of dystonic reactions and one case of 
oculogyric crisis (OGC) as part of the dystonic 
reaction during risperidone treatment have been 
reported in the literature (Dickson et al.,1994; 
Radford et al.,1995; Faulk et al ,1996). We report 
two patients with schizophrenia who developed 
OGC crises during risperidone treatment 
Case 1: Ms. A, a 22-year-old girl with 
DSM-IV paranoid schizophrenia for 8 months 
was hospitalised and treatment was initiated in 
the form of risperidone 1 mg bid on first day 
and 2 mg bid. from second day onwards Patient 
did not receive any concomitant medication 
except lorazepam 2 mg h.s. After four days of 
treatment with risperidone, Ms A started having 
repeated episodes of upward deviation and 
fixation of eyeballs, with no other associated 
dystonic reaction, which would be relieved after 
giving promethazine, 25 mg i.m. Tablet 
trihexyphenidyl 2 mg t.id. was added which 
successfully prevented these episodes 
Case 2: Mrs. S, a 40-year-old lady with 
DSM-IV undifferentiated schizophrenia for 17 
years presented with prominent negative 
symptoms. During 17 years of her illness, she 
received trials of various antipsycotics including 
chlorpromazine, haloperidol, trifluoperazine and 
fluphenazme decanoate without significant 
improvement in negative symptoms After 
hospitalisation, previous medications were 
gradually discontinued and risperidone was 
started with gradual dosage increment, i.e. 1 mg 
bid on first day, 2mg bid on second day and 
3 mg bid then on. On the sixth day of treatment, 
she developed episodes of upward fixed gaze, 
which used to subside on giving promethazine, 
25mg i.m. The frequency of such episodes did 
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not decrease after reduction of risperidone 
dosage to 2 mg bid. Addition of trihexyphenidyl 
2 mg bid. stopped further episodes. 
OGC is described as a form of acute drug-
induced dyskinesia, where attack begins as a 
fixed stare and the eyes rotate upwards or 
sideways and fix in position. The most common 
cause of OGC is treatment with antipsychotics 
or other antidopaminergic drug. Risperidone is 
being considered as a first line antipsychotic due 
to relative freedom from extrapyramidal 
symptoms in therapeutic dose range. Studies 
using multiple doses of risperidone have shown 
that this medication causes a dose-related 
increase in extrapyramidal side effects (Marder 
and Meibach,1994; Peuskens, 1995). Several 
of these studies indicate that the severity of 
extrapyramidal side effects with risperidone is 
lower than with conventional antipsychotic 
medications. In our cases, occurrence of OGC 
during risperidone treatment suggests that acute 
dystonic reactions and extrapyramidal symptoms 
can occur with low doses of risperidone also, 
though the risk may be lower than conventional 
antipsychotics. To ensure compliance, we should 
monitor patients closely during treatment with 
antipsychotic medications, whether conventional 
or atypical. 
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